Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
Chemistry World May 19, 2015 Phillip Broadwith	GSK commits to HIV research GlaxoSmithKline has reaffirmed its commitment to researching new drugs for HIV -- Aids, by partnering with the University of North Carolina in Chapel Hill, US.
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	HIV: Better Combos and Classes Keep Coming The new class of integrase inhibitors is the main event on the calendar, as Gilead's elvitegravir and ViiV Healthcare's GSK 1349572 come online in 2013 and 2014, respectively.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
The Motley Fool September 20, 2011 Brian Orelli	Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell?
The Motley Fool July 17, 2009 Brian Orelli	Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
Salon.com July 17, 2000 Nina Teicholz	When drugs take a holiday Could taking a break from protease inhibitors be the secret to treating AIDS? A new case of a 40-year-old man in Philadelphia shows it's possible.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
BusinessWeek September 12, 2005 John Carey	A Better Way To Ambush AIDS? HIV increasingly outwits today's drugs even as side effects take a toll. But Panacos Pharmaceuticals' experimental drug opens the door to a new line of attack.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
Chemistry World January 11, 2016 Phillip Broadwith	GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
Pharmaceutical Executive July 30, 2007 Walter Armstrong	Tibotec Gets AIDS With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, Tibotec is in it to win it. And end it.
The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
The Motley Fool December 21, 2004 Brian Gorman	Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients.
The Motley Fool June 26, 2008 Brian Lawler	Ardea Takes the More Exciting Route Ardea Bioscicences announces phase 2a data for its lead anti-HIV drug that is good enough to encourage further testing.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
Popular Mechanics December 1, 2006 Ben Harder	Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides.
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
BusinessWeek February 10, 2011 Rob Waters	Sangamo's Bet Against AIDS: Gene Therapy Sangamo's stock has more than doubled since July 6, when the company, with no products on the market, reported success of its gene therapy approach in mice in the journal Nature Biotechnology.
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
American Family Physician May 15, 2002	HIV in Women What are HIV and AIDS?... How do women become infected with HIV?... Is HIV infection different in women and men?... What precautions can be taken to avoid getting HIV during sex?... What should I do if I think I may be infected?...
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
American Family Physician August 1, 2000 Sharon Scott Morey	Practice Guidelines HHS Updates Guidelines for Antiretroviral Therapy in HIV Infection
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
Chemistry World August 3, 2006 Katharine Sanderson	New Drug Joins the Anti-HIV Armoury A treatment for drug-resistant HIV has been approved for use in the US. The milestone will lead to mass-produced treatments for other drug-resistant viruses in the developing world, its creators claim.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
Chemistry World April 27, 2007 Ned Stafford	New HIV Blocker Prepares for Trials Scientists who isolated a natural component of human blood that defends against the HIV-1 virus are now moving quickly to test their ideas clinically in the hope of bringing a new class of HIV-blockers based on peptide therapeutics to market.
Chemistry World March 10, 2008 Victoria Gill	New Hope for Anti-HIV Gels Early data from a clinical trial has rekindled hope of an effective topical gel to prevent HIV infection.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool April 1, 2011 Brian Orelli	Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse.
The Motley Fool August 9, 2011 Brian Orelli	Some Potential Good News in Biotech The FDA should approve Gilead's Btripla.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
The Motley Fool April 21, 2009 Brian Orelli	Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply.
Nursing August 2008 Carl A. Kirton	Managing Long-Term Complications of HIV Infection Now that advances in treatment have transformed HIV into a chronic, manageable disease, patients are facing cardiovascular and metabolic complications you might not have expected 15 years ago. Here's how to help your patient manage them.